Conditions: Arthritis, Rheumatoid
Keywords: oral JAK inhibitor MTX DMARD clinical trial joint diseases autoimmune diseases anti-Inflammatory agents rheumatic diseases
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 956
Healthy volunteers: no

Brief summary:
This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. This study will also compare the safety of CP-690,550 with methotrexate.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: CP-690,550 intervention 2: CP-690,550 intervention 3: Disease-modifying antirheumatic drug
Intervention descriptions: intervention 1: Oral tablets administered at a dose of 5 mg BID for 24 months intervention 2: Oral tablets administered at a dose of 10 mg BID for 24 months intervention 3: Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months

Protocol document: